2-substitutedalkyl N-{3-acetamido-4-[(2-cyano-4,6-disubstitutedphenyl)diazenyl]phenyl}-N-benzyl-β-alaninate

Genetic toxicity: in vitro

Administrative data

Endpoint:

in vitro gene mutation study in mammalian cells

Remarks:

Type of genotoxicity: gene mutation

Type of information:

experimental study

Adequacy of study:

key study

Study period:

08 January 2015 to 30 April 2015

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Compliant with GLP and testing guidelines; coherence among data, results and conclusion.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2015

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)

Deviations:

no

GLP compliance:

yes

Type of assay:

mammalian cell gene mutation assay

Test material

Test material information

Constituent 1

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

Details on test material:

Test item: Disperse Blue 1092

Method

Target gene:

The test item Disperse Blue 1092 was examined for mutagenic activity by assaying for the induction of 6-thioguanine resistant mutants in Chinese
hamster V79 cells after in vitro treatment. 6-thioguanine can be metabolised by the enzyme hypoxanthine-guaninphosphoribosyl-transferase (HPRT) into nucleotides, which are used in nucleic acid synthesis resulting in the death of HPRTcompetent cells. HPRT-deficient cells, which are presumed to arise through
mutations in the HPRT gene, cannot metabolise 6-thioguanine and thus survive and grow in its presence.

Species / strain

Species / strain / cell type:

Chinese hamster lung fibroblasts (V79)

Details on mammalian cell type (if applicable):

- Type and identity of media: EMEM medium supplemented with 10% Foetal Calf Serum (EMEM complete)
- Properly maintained: yes; Permanent stocks of the V79 cells are stored in liquid nitrogen. Subcultures are prepared from the frozen stocks for experimental
use.
- Periodically checked for Mycoplasma contamination: yes
- The karyotype, generation time, plating efficiency and mutation rates (spontaneous and induced) have been checked in this laboratory.
- Periodically "cleansed" against high spontaneous background: yes

Metabolic activation:

with and without

Metabolic activation system:

S9 tissue fraction: Species: Rat; Strain: Sprague Dawley; Tissue: Liver Inducing Agents: Phenobarbital – 5,6-Benzoflavone Producer: MOLTOX, Molecular Toxicology, Inc. Batch Numbers: 3332, 3350 and 3417

Test concentrations with justification for top dose:

A preliminary cytotoxicity assay was performed. Based on solubility features, the test item was assayed at a maximum dose level of 39.1 μg/mL and at a wide range of lower dose levels: 19.6, 9.78, 4.89, 2.44, 1.22, 0.611, .0305 and 0.153 μg/mL.
Two independent assays for mutation to 6-thioguanine resistance were performed using the following dose levels:
Main Assay I (+S9): 78.1, 39.1, 19.5, 9.77, 4.88, and 2.44 μg/mL.
Main Assay I (-S9): 39.1, 19.5, 9.77, 4.88, and 2.44 μg/mL.
Main Assay II (+S9): 80.0, 44.4, 24.7, 13.7, 7.62 and 4.23 μg/mL.
Main Assay II (-S9): 40.0, 25.0, 15.6, 9.77, 6.10 and 3.81 μg/mL.

Vehicle / solvent:

Test item solutions were prepared using dimethylsulfoxide (DMSO).

Controls

Negative solvent / vehicle controls:

yes

Positive controls:

yes

Positive control substance:

7,12-dimethylbenzanthracene

ethylmethanesulphonate

Details on test system and experimental conditions:

A preliminary cytotoxicity test was undertaken in order to select appropriate dose levels for the mutation assays. Treatments were performed both in the absence and presence of S9 metabolism; a single culture was used at each test point and positive controls were not included.
Two mutation assays were performed including negative and positive controls, in the absence and presence of S9 metabolising system. Duplicate cultures were prepared at each test point, with the exception of the positive controls which were prepared in a single culture. On the day before the experiment, sufficient numbers of 75 cm2 flasks were inoculated with 2 million freshly trypsinised V79 cells from a common pool. The cells were allowed to attach overnight prior to treatment. Following treatment, the cultures were incubated at 37°C for three hours. At the end of the incubation period, the treatment medium was removed and the cell monolayers were washed with PBS. Fresh complete medium was added to the flasks which were then returned to the incubator at 37°C in a 5% CO2 atmosphere (100% nominal relative humidity) to allow for expression of the mutant phenotype.
Determination of survival: The following day, the cultures were trypsinised and an aliquot was diluted and plated to estimate the viability of the cells.
Subculturing:On Day 3, the cell populations were subcultured in order to maintain them
in exponential growth. When Day 8 is used as expression time, subculturing was performed on Day 4 and Day 6.
Determination of mutant frequency: A single expression time was used for each experiment. Day 8 (Main I) and Day 6 (Main II) were used alternatively in the experiments. At the expression time, each culture was trypsinised, resuspended in complete medium and counted
by microscopy. After dilution, an estimated 1 x 10^5cells were plated in each of five 100 mm tissue culture petri dishes containing medium supplemented
with 6-thioguanine (at 7.5 μg/mL). These plates were subsequently stained with Giemsa solutions and scored for the presence of mutants. After dilution,
an estimated 200 cells were plated in each of three 60 mm tissue culture petri dishes. These plates were used to estimate Plating Efficiency (P.E.).

Evaluation criteria:

For a test item to be considered mutagenic in this assay, it is required that:
– There is a five-fold (or more) increase in mutation frequency compared with the solvent controls, over two consecutive doses of the test item. If only the highest practicable dose level (or the highest dose level not to cause unacceptable toxicity) gives such an increase, then a single treatment-level will suffice.
– There must be evidence for a dose-relation (i.e. statistically significant effect in the ANOVA analysis).

Statistics:

The results of these experiments were subjected to an Analysis of Variance in which the effect of replicate culture, expression time and dose level in
explaining the observed variation was examined. For each experiment, the individual mutation frequency values at each test point were transformed
to induce homogeneous variance and normal distribution. The appropriate transformation was estimated using the procedure of Snee and Irr (1981), and
was found to be y = (x + a)b where a = 0 and b = 0.275. A two way analysis of variance was performed (without interaction) fitting to two factors:
– Replicate culture: to identify differences between the replicate cultures treated.
– Dose level: to identify dose-related increases (or decreases) in response, after allowing for the effects of replicate cultures and expression time.
The analysis was performed separately with the sets of data obtained in the absence and presence of S9 metabolism.

Results and discussion

Test results

Species / strain:

Chinese hamster lung fibroblasts (V79)

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

cytotoxicity

Vehicle controls validity:

valid

Positive controls validity:

valid

Additional information on results:

Survival after treatment:
In Main Assay I, no relevant toxicity was observed at any concentration tested, in the absence or presence if S9 metabolic activation.
In Main Assay II, in the absence of S9 metabolism, mild toxicity was observed at the two highest dose levels of 25.0 and 40.0 μg/mL reducing survival to 61% and 55%, respectively; while no relevant toxicity was noted over the remaining concentrations tested. In the presence of S9 metabolism, no relevant toxicity was observed at any concentration tested.

Mutation results:
No relevant increases over the spontaneous mutation frequency were observed in any experiment, at any treatment level either in the absence or presence of S9 metabolic activation. Analysis of variance indicated that dose levels and replicate culture were not significant factors in explaining the observed variation in the data, in the absence and presence of S9 metabolism, in Main Assay I and II.

Remarks on result:

other: all strains/cell types tested

Remarks:

Migrated from field 'Test system'.

Applicant's summary and conclusion

Conclusions:

Interpretation of results (migrated information):
negative

It is concluded that Disperse Blue 1092 does not induce mutation in Chinese hamster V79 cells after in vitro treatment, in the absence or presence of S9 metabolic activation, under the reported experimental conditions.

Executive summary:

The test item Disperse Blue 1092 was examined for mutagenic activity by assaying for the induction of 6-thioguanine resistant mutants in Chinese hamster V79 cells after in vitro treatment. Experiments were performed both in the absence and presence of metabolic activation, using liver S9 fraction from rats pre-treated with phenobarbitone and beta-naphthoflavone. Test item solutions were prepared using dimethylsulfoxide (DMSO). A preliminary cytotoxicity assay was performed. Based on solubility features, the test item was assayed, in the absence and presence of S9 metabolism, at a maximum dose level of 39.1 μg/mL and at a wide range of lower dose levels: 19.6, 9.78, 4.89, 2.44, 1.22, 0.611, .0305 and 0.153 μg/mL. A reduction of cell viability was observed at the two highest dose levels (39.1 and 19.6 μg/mL), in the absence of S9 metabolism while no relevant toxicity was observed at any dose levels, in the presence of S9 metabolism. Precipitation of the test item was noted at the highest concentration tested (39.1 μg/mL), in the absence and presence of S9 metabolism; a coloured film, adhering to the flask surface, was noted starting from 2.44 μg/mL, in the absence of S9 metabolism. Two independent assays for mutation to 6-thioguanine resistance were performed using the following concentrations:

Main Assay I (+S9): 78.1, 39.1, 19.5, 9.77, 4.88, and 2.44 μg/mL.

Main Assay I (-S9): 39.1, 19.5, 9.77, 4.88, and 2.44 μg/mL.

Main Assay II (+S9): 80.0, 44.4, 24.7, 13.7, 7.62 and 4.23 μg/mL.

Main Assay II (-S9): 40.0, 25.0, 15.6, 9.77, 6.10 and 3.81 μg/mL.

Since, in the preliminary toxicity test, no precipitation of the test item was noted in the presence of S9 metabolic activation, in the first experiment 78.1 μg/mL was selected as the maximum dose level to be tested in the presence of S9 metabolism. The concentration range of the second experiment was slightly modified on the basis of the results obtained in the first experiment. No reproducible five-fold increases in mutant numbers or mutant frequency were observed following treatment with the test item at any dose level, in the absence or presence of S9 metabolism. Negative and positive control treatments were included in each mutation experiment in the absence and presence of S9 metabolism. Marked increases were obtained with the positive control treatments indicating the correct functioning of the assay system. It is concluded that Disperse Blue 1092 does not induce gene mutation in Chinese hamster V79 cells after in vitro treatment in the absence or presence of S9 metabolic activation, under the reported experimental conditions.